Christine Bayer Selected Research

Squamous Cell Carcinoma (Epidermoid Carcinoma)

1/2017	Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.
1/2017	Matching the reaction-diffusion simulation to dynamic [18F]FMISO PET measurements in tumors: extension to a flow-limited oxygen-dependent model.
12/2014	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
1/2014	Preclinical evaluation of parametric image reconstruction of [18F]FMISO PET: correlation with ex vivo immunohistochemistry.
11/2012	Monitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation.
2/2010	Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
3/2008	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck.
5/2007	Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christine Bayer Research Topics

Disease

16	Neoplasms (Cancer) 08/2017 - 02/2008
14	Hypoxia (Hypoxemia) 01/2017 - 05/2007
8	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017 - 05/2007
6	Squamous Cell Carcinoma of Head and Neck 08/2017 - 07/2007
3	Neoplasm Metastasis (Metastasis) 08/2017 - 12/2014
3	Head and Neck Neoplasms (Head and Neck Cancer) 08/2017 - 06/2011
3	Carcinoma (Carcinomatosis) 12/2014 - 07/2007

Drug/Important Bio-Agent (IBA)

8	pimonidazoleIBA 01/2017 - 03/2008
5	Cisplatin (Platino)FDA LinkGeneric 08/2017 - 02/2008
5	Proteins (Proteins, Gene)FDA Link 01/2016 - 05/2007
5	Plasminogen Activator Inhibitor 1IBA 11/2012 - 05/2007
4	fluoromisonidazoleIBA 01/2017 - 06/2011
4	Plasminogen InactivatorsIBA 11/2012 - 05/2007
4	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 11/2012 - 04/2011
3	Biomarkers (Surrogate Marker)IBA 08/2017 - 03/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 12/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2012 - 03/2008
2	Oxygen (Dioxygen)IBA 01/2017 - 05/2007
2	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 05/2015 - 01/2012
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 05/2015 - 01/2012
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 06/2014 - 03/2014
2	PlasminogenIBA 03/2008 - 05/2007
1	LigandsIBA 08/2017
1	Chemokine ReceptorsIBA 08/2017
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2017
1	Hematoxylin (Haematoxylon)IBA 01/2017
1	Radiation-Sensitizing AgentsIBA 05/2015
1	SuspensionsIBA 06/2014
1	AntigensIBA 11/2012
1	EnzymesIBA 11/2012
1	ImmunosorbentsIBA 11/2012
1	Growth Factor ReceptorsIBA 01/2012
1	tanespimycin (17AAG)IBA 01/2012
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 02/2010
1	Small Interfering RNA (siRNA)IBA 02/2010
1	Pharmaceutical PreparationsIBA 02/2008
1	Tirapazamine (SR 4233)IBA 02/2008
1	Messenger RNA (mRNA)IBA 05/2007
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2007
1	Urokinase Plasminogen Activator ReceptorsIBA 05/2007

Therapy/Procedure

7	Radiotherapy 06/2014 - 07/2007
4	Chemoradiotherapy 08/2017 - 12/2014
3	Therapeutics 01/2017 - 06/2011
1	Drug Therapy (Chemotherapy) 08/2017
1	Adjuvant Radiotherapy 08/2017
1	Injections 02/2008